Company intelligence / Profile preview

Livonian Biotech Millennium

Riga, Latvia

Ownership: Private
Employees: ~5
Development stage: Other

Overview

The company's lead drug candidate, G2013 (alpha-L-guluronic acid), has completed Phase 2 clinical trials for secondary progressive multiple sclerosis (SPMS) and rheumatoid arthritis (RA). Results showed significant improvement in disability progression and reduction in relapse rates for MS patients compared to conventional treatments, with a high safety profile. The company also markets the commercial joint relief gel Livalgel-M.

Therapeutic areas: ImmunologyNeurologyInfectious DiseasesRheumatologyGastroenterology
Modalities: Small moleculeAlginate derivatives
Industry: Biotech

Drug pipeline

1 asset

Livalgel-M

Unknown

Partnerships

Institute of Innovative Biomedical TechnologiesTehran University of Medical SciencesInstitute of Biology of the University of Latvia

Beyond the preview

Go deeper on Livonian Biotech Millennium.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Livonian Biotech Millennium.

Explore the full profile